MST-0300

N/A

Report date: 2024/08/29 17:07:03
First In Class

Base Information

Drug NameMST-0300
Drug Alias NameMST-0300
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionFibroblast activation protein alpha modulatorsTumor necrosis factor receptor superfamily member 3 agonists
TargetsTumor necrosis factor receptor superfamily member 3Prolyl endopeptidase FAP
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMestag Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovate UkMestag Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A